|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155.51 USD | +0.84% |
|
+2.20% | +13.93% |
| Capitalization | 15.51B 13.33B 12.49B 11.64B 21.5B 1,395B 23.38B 146B 56.39B 659B 58.19B 56.95B 2,410B | P/E ratio 2025 * |
30.8x | P/E ratio 2026 * | 22.4x |
|---|---|---|---|---|---|
| Enterprise value | 13.76B 11.83B 11.08B 10.33B 19.07B 1,238B 20.75B 130B 50.04B 585B 51.64B 50.54B 2,138B | EV / Sales 2025 * |
4.82x | EV / Sales 2026 * | 3.85x |
| Free-Float |
98.7% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Neurocrine Biosciences, Inc.
| 1 day | +0.84% | ||
| 1 week | +2.20% | ||
| Current month | +2.20% | ||
| 1 month | +0.46% | ||
| 3 months | +7.92% | ||
| 6 months | +24.02% | ||
| Current year | +13.93% |
| 1 week | 149.58 |  | 156.76 |
| 1 month | 137.02 | | 156.76 |
| Current year | 84.23 | | 157.67 |
| 1 year | 84.23 | | 157.67 |
| 3 years | 84.23 | | 157.98 |
| 5 years | 71.88 | | 157.98 |
| 10 years | 31.25 | | 157.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Gano
CEO | Chief Executive Officer | 52 | 2024-10-10 |
| Director of Finance/CFO | 46 | 2017-10-31 | |
Sanjay Keswani
CTO | Chief Tech/Sci/R&D Officer | 55 | 2025-06-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 67 | 2007-12-31 |
Richard Pops
BRD | Director/Board Member | 63 | 1998-03-31 |
| Chairman | 77 | 2011-04-30 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 13.65% | 303 M€ | -21.21% | - |
| 3.81% | 1 M€ | 0.00% | - |
| 1.85% | 5 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.84% | +2.20% | +21.36% | +29.37% | 15.51B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| Average | -0.29% | -1.78% | +13.21% | +28.28% | 331.2B | |
| Weighted average by Cap. | -0.37% | -2.77% | +17.63% | +56.72% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.86B 2.46B 2.3B 2.14B 3.96B 257B 4.31B 26.9B 10.39B 121B 10.72B 10.49B 444B | 3.38B 2.9B 2.72B 2.54B 4.68B 304B 5.09B 31.82B 12.29B 144B 12.68B 12.41B 525B |
| Net income | 512M 440M 412M 384M 709M 46.05B 772M 4.82B 1.86B 21.75B 1.92B 1.88B 79.52B | 702M 604M 566M 527M 974M 63.2B 1.06B 6.61B 2.55B 29.85B 2.64B 2.58B 109B |
| Net Debt | -1.75B -1.5B -1.41B -1.31B -2.42B -157B -2.63B -16.45B -6.35B -74.24B -6.56B -6.42B -271B | -2.49B -2.14B -2B -1.87B -3.45B -224B -3.75B -23.44B -9.05B -106B -9.34B -9.14B -387B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 155.51 $ | +0.84% | 893,211 |
| 25-12-04 | 154.22 $ | +1.49% | 599,645 |
| 25-12-03 | 151.96 $ | -0.34% | 823,304 |
| 25-12-02 | 152.48 $ | +1.06% | 853,246 |
| 25-12-01 | 150.88 $ | -0.84% | 703,685 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NBIX Stock
Select your edition
All financial news and data tailored to specific country editions
